News >

Eng Expands on Evolving GI Cancer Landscape

Brandon Scalea
Published: Thursday, Aug 09, 2018

Cathy Eng, MD

Cathy Eng, MD
Recent clinical findings across gastrointestinal (GI) cancers addressed unanswered questions in a number of patient populations, said Cathy Eng, MD.

Furthermore, the ADORE trial provided data in the locally advanced rectal cancer setting. The study tested the addition of adjuvant oxaliplatin to leucovorin and 5-fluorouracil (5-FU; FOLFOX) versus leucovorin/5-FU alone. The primary endpoint of disease-free survival suggested a clear benefit with the addition of oxaliplatin.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Navigating Treatment Decisions in mCRC: Sequencing Through Multiple Lines of CareMar 26, 20201.5
Community Practice Connections™: Optimizing Care in the Era of an Expanding Armamentarium for Hepatocellular CarcinomaMar 29, 20202.0
Publication Bottom Border
Border Publication